TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05764928: A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404Oral Liquid Combined With Pemetrexed + Cisplatin Therapy in Patients With Advanced Inoperable or Metastatic EGFR Wild-type Non-Small Cell Lung Cancer Patients

Sponsor: Rgene Corporation · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 32 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT05764928 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05764928 Rescue Dossier →